Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
Department of Dentistry, Radboud University Medical Center, Nijmegen, the Netherlands.
Int Dent J. 2024 Dec;74(6):1424-1431. doi: 10.1016/j.identj.2024.04.014. Epub 2024 May 1.
Patients with PTEN hamartoma tumour syndrome (PHTS) have an increased risk of developing cancer due to a pathogenic germline variant in the PTEN tumour suppressor gene. Early recognition of PHTS facilitates initiation of cancer surveillance which is highly effective in preventing the development of advanced malignancies. PHTS is rare and due to its varied phenotype, even within families, oral abnormalities may be a valuable tool in the identification of these patients at an early stage before cancer development.
Between 1997 and 2020, phenotypic characteristics were evaluated in 81 paediatric (median age: 9 years) and 86 adult (median age: 40 years) PHTS patients by one of 2 medical experts during yearly surveillance visits at a Dutch PHTS expertise centre. Oral features evaluated included gingival hypertrophy, oral papillomas, and high palate (in adults).
Within adults, gingival hypertrophy was present in 94%, oral papillomas in 88%, and a high palate in 89%. All adult patients had at least one of these oral features, and 99% showed at least 2 oral features. Oral features were less common in paediatric patients, especially under 11 years of age. Gingival hypertrophy was observed in 44% and oral papillomas in 54% of paediatric patients.
The presence of 2 or 3 oral features may indicate PHTS in adults or adolescents, especially if macrocephaly is present. Dental professionals are well-positioned to recognise these oral manifestations could be related to PHTS. They can initiate an overall clinical assessment of the patient by alerting the patient's medical practitioner of the findings and the possible need for genetic testing. This could significantly improve outcomes, including life expectancy, for patients and possibly for their relatives.
Dental professionals are ideally placed to recognise oral features and initiate early assessment of PHTS which could significantly improve patient outcomes.
由于 PTEN 肿瘤抑制基因中的致病性种系变异,PTEN 错构瘤肿瘤综合征(PHTS)患者罹患癌症的风险增加。早期识别 PHTS 有助于启动癌症监测,这对于预防晚期恶性肿瘤的发生非常有效。PHTS 较为罕见,且由于其表现型多样,即使在家族内,口腔异常也可能是在癌症发生前早期识别这些患者的有价值的工具。
1997 年至 2020 年间,通过荷兰 PHTS 专业中心的 2 位医学专家在每年的监测就诊中对 81 名儿科(中位年龄:9 岁)和 86 名成人(中位年龄:40 岁)PHTS 患者的表型特征进行评估。评估的口腔特征包括牙龈增生、口腔乳头状瘤和腭高(成人)。
在成人中,牙龈增生占 94%,口腔乳头状瘤占 88%,腭高占 89%。所有成年患者均至少存在一种口腔特征,99%的患者存在至少两种口腔特征。在儿科患者中,口腔特征较为少见,尤其是 11 岁以下的患者。牙龈增生见于 44%的儿科患者,口腔乳头状瘤见于 54%的儿科患者。
2 种或 3 种口腔特征的存在可能提示成人或青少年患有 PHTS,尤其是存在大头畸形时。牙科专业人员可以识别这些口腔表现,这些表现可能与 PHTS 有关。他们可以通过向患者的医疗从业者报告这些发现以及可能需要进行基因检测的情况,来启动对患者的全面临床评估。这可以显著改善患者的预后,包括延长预期寿命,并且可能对患者及其亲属的预后产生影响。
牙科专业人员非常适合识别口腔特征并早期评估 PHTS,这可以显著改善患者的预后。